Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How on earth did 'Shark Tank' star Kevin O'Leary end up in 'Marty Supreme'? I'll let him explain. - 2Fossils from China show complex life evolved millions of years earlier than once thought
- 3Members of Kenya-led security mission in Haiti were involved in rapes, U.N. says
- 4Getting Your Youngsters' Future: Grasping Legacy Regulations
- 5Dick Van Dyke shares his secrets to longevity as he turns 100
- Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
- Moving Wedding Objections for Paramount Functions
- Hitting the brakes: Hubble Space Telescope watches doomed comet reverse its spin
- What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
- She just became the first wheelchair user to travel to space
- Bolsonaro discharged from hospital and placed under house arrest
- Stunning new James Webb Space Telescope images reveal 'hidden' stars being born
- Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
